Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ORLANDO, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Middle District of Florida has approved the following announcement of a...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Graphjet Technology (“Graphjet” or the “Company”) (NASDAQ: GTI). Such investors are...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sprinklr, Inc. (“Sprinklr” or the “Company”) (NYSE: CXM). Such investors are advised to...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. (“Biomea” or the “Company”) (NASDAQ: BMEA). Such investors are advised...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Uranium Energy Corp. (“UEC” or the “Company”) (NYSE: UEC). Such investors are advised to...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Target Hospitality Corp. (“Target Hospitality” or the “Company”) (NASDAQ: TH). Such...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are advised...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RH (“RH” or the “Company”) (NYSE: RH). Such investors are advised to contact Danielle...
-
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are...